IntelGenx Corp. Product Segmentation & Forecast - 2015

1
Intel Genx Corp.Product Pipeline Review - 2015
No. Pages 44
Published on October - 2015
2
.
Report Overview
About Intel Genx Corp. Product Pipeline Review -
2015 Global Markets Directs, Intel Genx Corp.
Product Pipeline Review - 2015, provides an
overview of the Intel Genx Corp. s,
pharmaceutical research and development focus.
This report provides comprehensive information on
the current therapeutic developmental pipeline of
Intel Genx Corp. s, complete with comparative
analysis at various stages, therapeutics
assessment by drug target, mechanism of action
(MoA), route of administration (RoA) and molecule
type. It also reviews latest updates, and
featured news and press releases, along with
special features on late-stage and discontinued
projects. Global Markets Directs report features
investigational drugs from across globe covering
over 20 therapy areas and nearly 3,000
indications. The report is built using data and
information sourced from Global Markets Directs
proprietary databases, Company/University
websites, SEC filings, investor presentations and
featured press releases from company/university
sites and industry-specific third party sources,
put together by Global Markets Directs team. Get
Full Details On http//www.researchbeam.com/inte
lgenx-corp-product-pipeline-review-2015-market

3
.
Report Overview
Drug profiles/records featured in the report
undergoes periodic updation following a stringent
set of processes that ensures that all the
profiles are updated with the latest set of
information. Additionally, processes including
live news deals tracking, browser based
alert-box and clinical trials registries tracking
ensure that the most recent developments are
captured on a real time basis. The report
enhances decision making capabilities and help to
create effective counter strategies to gain
competitive advantage. It strengthens RD
pipelines by identifying new targets and MOAs to
produce first-in-class and best-in-class
products. Note Certain sections in the report
may be removed or altered based on the
availability and relevance of data for the
indicated disease. Scope The report provides
brief overview of Five Prime Therapeutics,
Inc.including business description, key
information and facts, and its locations and
subsidiaries The report reviews current pipeline
of Five Prime Therapeutics, Inc.s human
therapeutic division and enlists all their major
and minor projects
4
.
Report Overview
The report features product description and
descriptive mechanism of action for key pipeline
products along with the products developmental
history and major milestones Special feature on
out-licensed and partnered product portfolio The
report summarizes all the dormant and
discontinued pipeline projects Latest company
statement Latest news and deals relating to the
Five Prime Therapeutics, Inc.s pipeline
products   Reasons to buy Evaluate Five Prime
Therapeutics, Inc.s strategic position with total
access to detailed information on its product
pipeline Assess the growth potential of Five
Prime Therapeutics, Inc.in its therapy areas of
focus Identify new drug targets and therapeutic
classes in the Five Prime Therapeutics, Inc.s RD
portfolio and develop key strategic initiatives
to reinforce pipeline in those areas Exploit
in-licensing opportunities by identifying windows
of opportunity to fill portfolio gaps
5
Report Overview

• Develop strategic initiatives by understanding
  the focus areas of Five Prime Therapeutics,
  Inc.and exploit collaboration and partnership
  opportunities
• Identify emerging players with potentially strong
  product portfolio and create effective
  counter-strategies to gain competitive advantage
• Plan mergers and acquisitions effectively by
  identifying the most promising pipeline of Five
  Prime Therapeutics, Inc.
• Develop and design in-licensing and out-licensing
  strategies by identifying prospective partners
  with the most attractive projects to enhance and
  expand business potential and Scope
• Explore the dormant and discontinued projects of
  Five Prime Therapeutics, Inc.and identify
  potential opportunities in those areas
• Avoid Intellectual Property Rights related issues

6
Table Of Contents
List of Tables 4List of Figures 4IntelGenx
Corp. Snapshot 5IntelGenx Corp. Overview 5Key
Information 5Key Facts 5IntelGenx Corp. -
Research and Development Overview 6Key
Therapeutic Areas 6IntelGenx Corp. - Pipeline
Review 8Pipeline Products by Stage of
Development 8Pipeline Products - Monotherapy
9Pipeline Products - Partnered Products
10Partnered Products/Combination Treatment
Modalities 11Pipeline Products - Out-Licensed
Products 12
7
Table Of Contents
Out-Licensed Products/Combination Treatment
Modalities 13IntelGenx Corp. - Pipeline Products
Glance 14IntelGenx Corp. - Clinical Stage
Pipeline Products 14Phase I Products/Combination
Treatment Modalities 14IntelGenx Corp. - Early
Stage Pipeline Products 15Preclinical
Products/Combination Treatment Modalities
15Discovery Products/Combination Treatment
Modalities 16IntelGenx Corp. - Drug Profiles
17INT-0028 17Product Description 17Mechanism
of Action 17RD Progress 17INT-0036 18Product
Description 18
8
Table Of Contents
Mechanism of Action 18 RD Progress 18metoprolol
succinate 19Product Description 19Mechanism of
Action 19RD Progress 19tadalafil 20Product
Description 20Mechanism of Action 20RD
Progress 20 INT-0031 21Product Description
21Enquiry about this report _at_ http//www.research
beam.com/intelgenx-corp-product-pipeline-review-20
15-market/enquire-about-report
9
FOR MORE DETAILS
Visit us at
http//www.researchbeam.com/intelgenx-corp-product
-pipeline-review-2015-market
Stay With Us
5933 NE Win Sivers Drive,205, Portland, OR
97220United States
TELEPHONE [phone] E-MAIL
sales_at_researchbeam.com